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Background and Aims: Heart failure with reduced ejection fraction (HFrEF) still carries
a high risk for a sustained decrease in left ventricular ejection fraction (LVEF) even with
the optimal medical therapy. Currently, there is no effective tool to stratify these patients
according to their recovery potential. We tested the hypothesis that uric acid (UA) could
predict recovery of LVEF and prognosis of HFrEF patients and attempted to explore
mechanistic relationship between hyperuricemia and HFrEF.
Methods: HFrEF patients with hyperuricemia were selected from the National
Inpatient Sample (NIS) 2016–2018 database and our Xianyang prospective cohort study.
Demographics, cardiac risk factors, and cardiovascular events were identified. Networkbased analysis was utilized to examine the relationship between recovery of LVEF and
hyperuricemia, and we further elucidated the underlying mechanisms for the impact of
hyperuricemia on HFrEF.
Results:
After adjusting confounding factors by propensity score matching,
hyperuricemia was a determinant of HFrEF [OR 1.247 (1.172–1.328); P < 0.001]
of NIS dataset. In Xianyang prospective cohort study, hyperuricemia is a significant
and independent risk factor for all-cause death (adjusted HR 2.387, 95% CI 1.141–
4.993; P = 0.021), heart failure readmission (adjusted HR 1.848, 95% CI 1.048–3.259;
P = 0.034), and composite events (adjusted HR 1.706, 95% CI 1.001–2.906; P = 0.049)
in HFrEF patients. UA value at baseline was negatively correlated to LVEF of follow-ups
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(r = −0.19; P = 0.046). Cutoff UA value of 312.5 µmmol/L at baseline can work as a
predictor of LVEF recovery during follow-up, with the sensitivity of 66.7%, the specificity
of 35.1%, and the accuracy of 0.668 (95% CI, 0.561–0.775; P = 0.006). Moreover,
gene overlap analysis and network proximity analysis demonstrated a strong correlation
between HFrEF and Hyperuricemia.
Conclusion: Lower baseline UA value predicted the LVEF recovery and less longterm adverse events in HFrEF patients. Our results provide new insights into underlying
mechanistic relationship between hyperuricemia and HFrEF.
Keywords: uric acid, network analyses, heart failure with a reduced ejection fraction, recovery of left ventricular
ejection fraction, heart failure with recovery ejection fraction

INTRODUCTION

MATERIALS AND METHODS

Medical regimen can improve the clinical outcomes of heart
failure with reduced ejection fraction (HFrEF) and lead to a
reverse left ventricular (LV) remodeling in HFrEF patients (1,
2). However, the degree of reverse remodeling is extremely
variable, some patients might not have any reverse remodeling
with persistently reduced LV ejection fraction (LVEF) and
heart failure phenotype, whereas other patients can have
completely myocardial recovery with increased LVEF, decreased
LV volume and mass (1–4). At present, clinical variables
and validated clinical indices cannot accurately predict the
direction or extent of LVEF recovery after treated with optimal
pharmacologic therapy. Thus, the identification of potential
responders to therapy vs. non-responders remains a major
unmet need.
Uric acid (UA) is a metabolic decomposition product of
purine nucleotides, the relationship between serum UA and
cardiovascular diseases, especially for heart failure (HF), has
received extensive attention during past few decades (5). Various
studies have demonstrated that hyperuricemia was related
with higher morbidity and mortality in chronic HF (6–8)
and acute HF (9, 10). It was previously proposed that the
higher UA in chronic HF is resulted from the up-regulation
of the xanthine oxidase, which is an important enzyme for
UA metabolism and oxygen free radicals production. Increased
production of the oxygen free radicals can lead to impaired
vascular function (11), oxidative metabolism dysfunction (12),
and inflammatory cytokine activation (13). However, there is
still a lack of UA cut-off value to predict LVEF recovery and
long-term prognosis of HFrEF patients in clinical practice, and
the mechanistic relationship between hyperuricemia and HFrEF
remains unclear.
Here, we hypothesize that UA is potentially associate with
the recovery of LVEF, serves as an important predictor for the
LVEF recovery and prognosis in HFrEF patients. To this end, we
investigated the association of hyperuricemia and HFrEF using
data from the National Inpatient Sample (NIS) database and our
Xianyang prospective cohort study. Additionally, we performed
gene overlap and protein-protein interaction network analyses
to explore the underlying mechanistic relationship between
hyperuricemia and HFrEF.

A detailed methods
Tables S1, S2.
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RESULTS
Characteristics of Study Participants
Selected From NIS Database
Hyperuricemia was present in 0.74% (n = 13,468) of in-hospital
admissions and it was more common in patients with HFrEF
than the patients without HFrEF (0.2 vs. 0.07%; P < 0.001).
HFrEF patients were older (69.49 vs.57.29; P < 0.001) and less
likely to be females (38.6 vs. 58.8%; P < 0.0001) compared with
patients without HFrEF. Moreover, these HFrEF patients suffered
more from most traditional cardiac risk factors, including obesity
(15.3 vs.17.3%; P < 0.0001), hyperlipidemia (51.8 vs. 31.3%; P
< 0.0001), tobacco use (28.8 vs.19.9%; P < 0.0001), peripheral
vascular disease (2.9 vs.1.5%; P < 0.0001), carotid artery disease
(1.9 vs.1.3%; P < 0.0001), prior myocardial infarction (19.5
vs.4.8%; P < 0.0001), prior coronary aorta bypass graft (CABG)
(26.9 vs.7.9%; P < 0.0001). An increased in-hospital mortality
(5.1 vs. 2.1%; P < 0.0001), length of hospital stay (6.37 vs. 4.66%;
P < 0.0001) and total medical expenses (79,313.65 vs. 52,283.83;
P < 0.0001) were observed in HFrEF patients compared to the
patients without HFrEF (Supplementary Table S4).

Hyperuricemia Is Associated With the Risk
of HFrEF and In-hospital Complications in
NIS Database
Regression analysis demonstrated that hyperuricemia was
a determinant of HFrEF [OR 2.138 (2.019–2.55); P <
0.001] (Supplementary Figure S2), and hyperuricemia remained
strongly associated with HFrEF after adjusting for other
confounding risk factors, including age, gender, race, diabetes
mellitus, hypertension, hyperlipidemia, obesity, tobacco use,
coronary artery disease, atrial fibrillation, peripheral vascular
diseases, carotid artery stenosis, cerebral infarction, myocardial
infarction, stroke, prior percutaneous coronary intension (PCI)
and prior CABG [OR 1.247 (1.172–1.328); P < 0.001] (Figure 1).
To determine whether hyperuricemia in HFrEF patients
leads to higher risk of in-hospital mortality, acute organ failure
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FIGURE 1 | Multivariable logistic analysis results of relationship between hyperuricemia and HFrEF in NIS database 2016-2018. PCI, Percutaneous
coronary intervention.

group saw increased all-cause death rate (43.8 vs. 22.1%;
P = 0.068), HF readmission (81.3 vs. 56.1%; P = 0.06)
and composite outcomes events (87.5 vs. 65.1%; P = 0.076)
(Supplementary Table S5).
Multivariate Cox regression analysis showed that HFrEF
patients with hyperuricemia (UA ≥ 420 µmmol/L) had higher
risks for all-cause death (adjusted HR 2.387, 95% CI 1.141–4.993;
P = 0.021), HF readmission (adjusted HR 1.848, 95% CI 1.048–
3.259; P = 0.034), and composite events (adjusted HR 1.706, 95%
CI 1.001–2.906; P = 0.049) compared with HFrEF patients with
normal serum UA (Figure 2).
Kaplan-Meier survival curves displayed different event free
survival for all-cause death (HR = 2.39, log-rank P =
0.049, Figure 3A), readmission (HF = 2.19, log-rank P =
0.013, Figure 3B), and composite events (HR = 1.89, logrank P = 0.033, Figure 3C) between HFrEF patients with and
without hyperuricemia.

and mechanical circulatory support, propensity score matching
(PSM) was applied to reduce the bias due to confounding
variables (Table 1). The results demonstrated that HFrEF patients
with hyperuricemia presented with longer length of hospital
stay (7.60 vs. 6.45; P < 0.0001), more acute respiratory failure
(17.39 vs. 13.42%; P = 0.006), acute renal failure (67.59 vs.
36.70%; P < 0.0001), sudden cardiac arrest (1.75 vs. 0.79%; P
= 0.033), ventilator use (7.94 vs. 3.57%; P < 0.0001), intraaortic balloon pump (IABP) implantation (1.43 vs. 0.32%; P
= 0.003), and PCI (3.65 vs. 2.14%; P = 0.024). However,
there was no significant difference in hospital mortality between
HFrEF patients with and without hyperuricemia (4.37 vs. 5.65%;
P = 0.169) (Table 1).

Hyperuricemia Associated With the
Long-Term Outcomes of HFrEF Patients in
the Xianyang Chronic Heart Failure
Prospective Cohort

Hyperuricemia Is Associated With the
Recovery of LVEF in HFrEF Patients in the
Xianyang Chronic Heart Failure
Prospective Cohort

As shown in Supplementary Figure S5, a total of 102 patients
met our inclusion criteria, with 86 patients (84.3%) in UA
≤ 420 ummol/L group and 16 patients (15.7%) in UA >
420 ummol/L group. The average age of participants was
61.1 and 61.7% of them were male (Supplementary Table S5).
Characteristics of the patients in this study were shown in
Supplementary Table S5.
There were 102 patients followed up with a mean duration
of 33.44 months. During that time, 26 patients (25.5%) died,
59 patients (57.84%) had remission. The UA ≥ 420 µmmol/L
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In order to assess if hyperuricemia is related with the
recovery of LVEF in HFrEF patients, we divided the patients
into persistent HFrEF group (45, 44.1%) and heart failure
with recovery ejection fraction (HFrecEF) group (57, 49%)
according to their baseline LVEF and 1 year follow-up
LVEF (Supplementary Figure S1). The baseline characteristics

3

July 2022 | Volume 9 | Article 853870

Wang et al.

Risk Stratification of Recovered Ejection Fraction

TABLE 1 | Demographics and outcomes of patients with Heart Failure with Reduced Ejection Fraction, National Inpatient Sample (NIS) 2016–2018.
Unmatched groups

Propensity-matched groups

Characteristic

HFrEF without
hyperuricemia
(n = 865,772)

HFrEF with
hyperuricemia
(n = 1,302)

P-value

HFrEF without
hyperuricemia
(n = 1,259)

HFrEF with
hyperuricemia
(n = 1,259)

P-value

Age, yrs (mean ± SD)

69.49 ± 14.16

69.12 ± 14.16

0.342

68.10 ± 14.18

69.07 ± 14.16

0.085

Female, %

318,904 (36.8)

433 (33.3)

0.007

412 (32.72)

423 (33.60)

Race

0.641
0.464

<0.001

White, %

562,256 (66.9)

777 (61.2)

777 (61.72)

771 (61.24)

African American, %

164,692 (19.6)

280 (22.0)

278 (22.08)

276 (21.92)

Hispanic, %

69,547 (8.3)

116 (9.1)

106 (8.42)

116 (9.21)

Asian/Pacific Islander, %

17,527 (2.1)

48 (3.8)

35 (2.78)

48 (3.81)

Native American, %

4,751 (0.6)

6 (0.5)

9 (0.71)

6 (0.48)

Other races, %

21,905 (2.6)

43 (3.4)

54 (4.29)

42 (3.34)

Comorbidity
Coagulopathy, %

25,481 (2.9)

52 (4.0)

0.025

53 (4.21)

50 (3.97)

0.763

Obesity, %

149,757 (17.3)

338 (26)

<0.001

312 (24.78)

325 (25.81)

0.551

Hypertension, %

117,078 (13.5)

84 (6.5)

<0.001

82 (6.51)

83 (6.59)

0.936

Hypothyroidism, %

128,087 (14.8)

220 (16.9)

0.033

208 (16.52)

214 (17.00)

0.749

Coronary artery disease, %

530,813 (61.3)

775 (59.5)

0.186

721 (57.27)

749 (59.49)

0.258

Atrial fibrillation, %

374,078 (43.2)

546 (41.9)

0.355

495 (39.32)

523 (41.54)

0.256

Diabetes mellitus, %

390,624 (45.1)

624 (47.9)

0.042

612 (48.61)

606 (48.13)

0.811

Cerebral infarction, %

24,196 (2.8)

21 (1.6)

0.01

24,679 (2.9)

38 (2.9)

0.883

27 (2.14)

37 (2.94)

0.205

448,279 (51.8)

716 (55.0)

0.02

692 (54.96)

685 (54.41)

0.779

40,648 (4.7)

50 (3.8)

0.145

50 (3.97)

48 (3.81)

0.837

249,362 (28.8)

387 (29.7)

0.463

358 (28.44)

371 (29.47)

0.568

Peripheral vascular disease, %
Hypercholesteremia, %
Alcohol use, %
Tobacco abuse, %
In-hospital mortality, %

44,085 (5.1)

56 (4.3)

0.195

70 (5.56)

55 (4.37)

0.169

Length of hospital stay, days

6.37 ± 7.72

7.61 ± 6.79

<0.001

6.45 ± 7.27

7.60 ± 6.74

<0.001

Total charges, US$

79,306.03 ±
141,173.79

84,376.30 ±
118,821.790

0.197

87,196.87 ±
192,315.06

85,116.90 ±
119,822.18

0.745

Acute organ failure
Acute respiratory failure, %

138,930 (16.0)

174 (13.4)

0.008

169 (13.42)

219 (17.39)

0.006

Acute renal failure, %

287,968 (33.3)

883 (67.8)

<0.001

462 (36.70)

851 (67.59)

<0.001

Acute hepatic failure, %

13,956 (1.6)

30 (2.3)

0.048

27 (2.14)

29 (2.30)

0.787

Acute pulmonary edema, %

4,420 (0.5)

8 (0.6)

0.599

7 (0.56)

8 (0.64)

0.796

Hematodialysis, %

58,169 (6.7)

121 (9.3)

<0.001

Ventricular fibrillation, %

11,795 (1.4)

12 (0.9)

0.17

22 (1.75)

12 (0.95)

0.084

Cardiac shock, %

36,546 (4.2)

55 (4.2)

0.996

61 (4.85)

54 (4.29)

0.504

Sudden cardiac arrest, %

18,184 (2.1)

11 (0.8)

0.002

9.9 (0.79)

22 (1.75)

0.033

Cardio-pulmonary resuscitation, %

10,694 (1.2)

8 (0.6)

0.043

11 (0.87)

8 (0.64)

0.49

Ventilator use, %

64,044 (7.4)

46 (3.5)

<0.001

45 (3.57)

100 (7.94)

<0.001

LVAD, %

1,693 (0.2)

4 (0.4)

0.362

4 (0.32)

4 (0.32)

1

IABP, %

8,872 (1.0)

5 (0.4)

0.022

4 (0.32)

18 (1.43)

0.003

Mechanical circulatory support

ECMO, %

1,344 (0.2)

0 (0)

0.155

5 (0.40)

0 (0.00)

0.062

PCI, %

39,174 (4.5)

27 (2.1)

<0.001

27 (2.14)

46 (3.65)

0.024

CABG, coronary artery bypass grafting; LVAD, left ventricular assist device; PCI, percutaneous coronary intervention; MI, myocardial infarction; ECHO, extracorporeal
membrane oxygenation.

identified at baseline value of common echocardiographic
parameters (Supplementary Figure S3) between two groups,
HFrecEF group showed significantly increased LVEF and LVFS

of the two groups were shown in Table 2. The persistent
HFrEF group had higher UA (358.76 vs. 307.45; P = 0.004)
than HFrecEF group. While no significant difference was
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FIGURE 2 | Multivariable cox analysis for hazard ratios of outcomes associated with UA. (A) Multivariable cox analysis results of relationship between UA and all-cause
mortality. (B) Multivariable cox analysis results of relationship between UA and heart failure readmission. (C) Multivariable cox analysis results of relationship between
UA and composite outcomes events. BMI, body mass index; LVEF, left ventricle ejection fraction; UA, uric acid; NT-proBNP, N-terminal pro brain natriuretic peptide.

FIGURE 3 | Hyperuricemia associated with clinical events in HFrEF patients. (A) Kaplan–Meier survival plots for the all-cause death. (B) Readmission due to
worsening HF. (C) Composite end points in hyperuricemia and normal UA groups. UA, uric acid.

higher mortality compared with HFrecEF patients (HR = 2.31,
log-rank P = 0.037, Figure 4A).
Our results displayed that initial UA value had no statistically
significant correlation with LVEF at baseline (r = −0.11, P =
0.261; Figure 4B), but a significantly negative correlation with

and significantly decreased LV end-diastolic diameter (LVEDD),
LV end-systolic diameter (LVESD), LV end-diastolic volume
(LVEDV), LV end- systolic volume (LVESV) after 1 year
evidence-dependent medical treatment. Similar with previous
studies, our study demonstrated that the HFrEF patients had
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TABLE 2 | Baseline characteristics of the persistent HFrEF and HFrecEF.
Characteristics

Total (n = 102)

Persistent HFrEF (n = 45)

HFrecEF (n = 57)

P-value

61.13 ± 9.14

59.69 ± 8.493

62.26 ± 9.540

0.159

63 (61.7)

34 (75.6)

29 (50.9)

0.011

23.32 ± 3.37

24.09 ± 3.396

22.74 ± 3.267

Demographics
Age, years
Male, %
BMI, kg/m2

0.685
0.160

Etiology, %
Dilated cardiomyopathy

60 (58.8)

23 (51.1)

37 (64.9)

Other

42 (41.2)

22 (48.9)

20 (35.1)

Hypertension

33 (32.35)

15 (33.3)

19 (33.3)

Diabetes mellitus

11 (10.8)

6 (13.3)

5 (8.7)

0.461

CAD

36 (35.3)

19 (42.2)

17 (29.8)

0.193

Smoking

54 (52.9)

29 (64.4)

25 (43.9)

0.039

Medical history, %
0.872

Laboratory data
Scr, umol/L

78.56 ± 15.51

80.73 ± 13.87

76.85 ± 16.61

0.210

BUN mmol/L

6.97 ± 2.11

6.51 ± 1.88

7.28 ± 2.22

0.084

UA, µmmol/L

330.08 ± 89.62

358.76 ± 91.95

307.45 ± 81.60

0.004

eGFR, ml/min/1.73 m2

71.70 ± 20.98

75.70 ± 20.35

68.54 ± 21.10

0.087

2,563.47 ± 3,036.51

2,729.10 ± 3,253.85

2,432.69 ± 2,877.4

0.629

126.26 ± 25.74

126.63 ± 25.21

126.04 ± 26.29

0.920

LV EDD, mm

71.44 ± 7.92

72.71 ± 6.95

70.44 ± 8.53

0.151

LV ESD, mm

59.75 ± 7.85

60.58 ± 6.69

59.09 ± 8.66

0.344

LVEF, %

31.56 ± 7.85

32.97 ± 4.49

30.44 ± 6.21

0.023

Follow-up time, months

33.44 ± 8.67

31.04 ± 8.33

35.33 ± 8.54

0.012

89 (87.3)

41 (91.1)

48 (84.2)

0.299

6 (5.8)

1 (2.2)

5 (8.8)

0.163

β-blocker

91 (89.2)

39 (86.7)

52 (91.2)

0.461

Aldosterone receptor antagonist

80 (78.4)

37 (82.2)

43 (75.4)

NT-proBNP, ng/L
QRS, ms
Echocardiographic data

Medication use, %
ACE inhibitor
ARB

0.408
0.723

NYHA, %
I

17 (16.7)

9 (20.0)

8 (14.3)

II

58 (56.9)

24 (53.3)

34 (60.7)

III

23 (22.5)

10 (22.2)

13 (23.2)

IV

3 (2.9)

2 (4.4)

1 (1.8)

All-cause mortality

26 (25.5)

15 (33.3)

11 (19.3)

0.106

Rehospitalization

59 (60.2)

21 (50.0)

38 (67.9)

0.074

Composite outcomes events

70 (68.6)

27 (60.0)

43 (75.4)

0.095

BMI, body mass index; CAD, coronary artery disease; Scr, serum creatinine; BUN, blood urea nitrogen; UA, Uric Acid; eGFR, estimated glomerular filtration rate; NT-pro BNP, N-terminal
B-type natriuretic peptide; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; ACE, angiotensin converting
enzyme; ARB, angiotensin receptor blocker.
Values are percent or means ± SD.

Network-Based Validation of Significant
Disease Relationship Between
Hyperuricemia and HFrEF

LVEF at follow-up (r = −0.19; P = 0.046, Figure 4C). And
the receiver operating characteristic curves (ROC) showed that
baseline UA cutoff of 312.5 µmmol/L had a sensitivity of 66.7%,
specificity of 35.1%, and accuracy of 0.668 (95% CI, 0.561–0.775;
P = 0.006) for predicting the LVEF recovery during follow-up
(Figure 4D).
Multi-logistic regression analysis (Figure 4E) revealed that
the likelihood of LVEF recovery at follow-up decreased by 0.6%
for each unit increase of baseline UA (OR = 0.994; 95% CI,
0.988–0.999; P = 0.03; Figure 4E).
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We performed gene overlap analysis to identify the potential
mechanistic relationship between hyperuricemia and HFrEF.
Gene sets from each HFrEF patients exhibited high correlation
with gene sets from hyperuricemia (P < 0.05, Figure 5A).
The largest number of overlapped genes were identified
between hyperuricemia and HFrEF_S30 (n = 19, P =
3.17E-20, Fisher’s exact test), followed by hyperuricemia vs.
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FIGURE 4 | The relationship between UA and left ventricle ejection fraction recovery in HFrEF patient. (A) Kaplan-Meier survival plots for the all-cause death in
persistently HFrEF and HFrecEF patients. (B) The relationship between UA and LVEF at baseline LVEF. (C) The relationship between UA and LVEF at follow-up LVEF.
(D) ROC curve for baseline UA and follow-up LVEF. (E) Multivariable logistic analysis results of relationship between UA and recovery of LVEF. BMI, body mass index;
LVEF, left ventricle ejection fraction; UA, uric acid; NT-proBNP, N-terminal pro brain natriuretic peptide; eGFR, estimated glomerular filtration rate; HFrEF, heart failure
with reduced ejection fraction; HFrecEF, heart failure with preserved ejection fraction.

GAA, UMOD, APOE, LEP, MTHFR, APOA1, XDH, CRP,
IL10, INS, ALDH2, KCNQ1, ALB, PPARG, REN, GPT, ESR1,
NLRP3, TNF. Moreover, the p-value of hyperuricemia vs.

HFrEF_S40 (n = 14, P = 6.76E-17, Fisher’s exact test)
and Hyperuricemia vs. HFrEF_S50 (n = 13, P = 1.40E-19,
Fisher’s exact test). The most common overlapped genes are:
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FIGURE 5 | Disease relationship between Hyperuricemia and HFrEF predicted by Fisher’s test and network proximity approaches. (A) Correlation analysis of
Hyperuricemia and HFrEF gene datasets. (B) Z-score and distance values of four group datasets. Nr of genes indicates number of genes in each dataset; Nr of
overlapped genes denotes number of overlapped genes between each two datasets; Group 1: Hyperuricemia vs. HFrEF_S30; Group 2: Hyperuricemia vs.
HFrEF_S40; Group 3: Hyperuricemia vs. HFrEF_S50; Group 4: Hyperuricemia vs. HFrEF_S60.

DISCUSSION

HFrEF_S50 is 1.95E-18, with the overlapped gene number
of 11.
We also found a strong correlation between hyperuricemia
and HFrEF using network proximity approach, which
proved the robustness of our result. As illustrated in
Figure 5B, all the four hyperuricemia-HFrEF pairs show
statistical significance (adjust P < 0.05). Taken together,
these data verified the significant correlations between
hyperuricemia and HFrEF diseases, which deserves
further investigation.

UA, a product of the metabolic breakdown of purine nucleotides,
serves as a predictor of morbidity and mortality in chronic
HF (6–8), as well as acute HF (9, 10). However, the predictive
value of UA for LVEF recovery and prognosis in HFrEF patients
have not been evaluated by evidence-based medical regimen.
In present study, we demonstrated that HFrEF patients with
lower baseline UA were more likely to undergo subsequent
recovery of LVEF. We also showed that the higher serum UA
was related to higher risk for the all-cause mortality, readmission
and combined all-cause death or readmission in HF patients.
These results were independent of other established risk factors
such as renal function, LVEF, diuretic use, age, and NYHA
functional class.
Alberto et al. previously demonstrated that in patients with
acute HFrEF, univariate analysis found that hyperuricemia were
associated with heart failure hospitalization or death, however,
after adjustment, hyperuricemia were not associated with heart
failure hospitalization or death (15). Conversely, in patients
with HFpEF, hyperuricemia was the only significant predictor
of the primary end point both in univariate and multivariate
analyses (15). Additionally, UA was inversely correlated with
the left ventricular systolic function (16). In the present
study, we demonstrated in chronic stable HFrEF patients the
hyperuricemia was associated with heart readmission and death.
We speculate that this difference may be due to the different
study populations.
However, these associations were not evaluated in HFrecEF.
Reverse cardiac remodeling and LVEF recovery after the
evidence-based medical therapies has become a major goal of

Network-Based Elucidation of Underlying
Mechanistic Relationship Between
Hyperuricemia and HFrEF
To explore the potential mechanistic relationship between
hyperuricemia and HFrEF, we developed a protein-protein
interaction (PPI) network of 14 overlapped disease genes
(HFrEF_S40) based on a comprehensive human protein
interactome database (14). The PPI network contains 117
edges interacting with 65 HFrEF genes and 6 hyperuricemia
genes (Figure 6A). Among them, ESR1 has the most frequent
gene connections (D = 36), followed by ALB (D = 24)
and APOA1 (D = 11), indicating their key roles in both
hyperuricemia and HFrEF. We further performed KEGG
pathway (Figure 6B) and gene oncology enrichment (Figure 6C)
analysis based on the genes within the PPI network. We
identified many upregulated biological processes that were
associated with blood microparticle and hormone receptor
binding, including reactive oxygen species metabolic process
(Figure 6C).
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FIGURE 6 | Underlying mechanisms exploration between Hyperuricemia and HFrEF. (A) A protein-protein interaction (PPI) network of overlapped genes. (B) KEGG
pathways annotation results. (C) Biological process, cellular component and molecular function enrichment results. The label font size and node size are proportional
to degree.

tremendous interpatient heterogeneity of uric acid metabolism.
The measurement of UA can help us to identify HFrEF patients
with a potential possibility of LVEF recovery.
The mechanism by which UA affects the LVEF recovery
and long-term prognosis of HFrEF patients remains unclear.
Our gene network-based results revealed the strong correlation
between HFrEF and hyperuricemia, and further mechanism
exploration analysis indicated that disease-related genes were
involved with multiple inflammation pathways (e.g., autophagy
and TNF signaling pathway) and biological processes (e.g.,
reactive oxygen species metabolic process and hormone
receptor). Accumulating evidence demonstrated that the
management of urate-induced inflammasome or augmentation
of autophagy may provide the novel effective therapies for

contemporary medical and device treatment (17). While optimal
pharmacologic therapies can reverse the cardiac remodeling and
improve clinical outcomes, the degree of reverse remodeling is
extremely variable. Some patients might not have any reverse
remodeling and suffer persistent LVEF reduction and heart
failure phenotype after standard treatment (4, 18). HFrEF has
a spectrum range of different cellular, molecular and anatomic
changes, which means HFrEF patients can exhibit different
process of reverse LV remodeling. Part of them have completely
myocardial recovery with increased LVEF, decreased LV volume
and mass, whereas others might not have any reverse remodeling
with persistently reduced EF (19). Our results are consistent with
this point of view. Furthermore, we demonstrate that HFrEF
patients have a wide spectrum of UA values, which may cause by
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CONCLUSION

hyperuricemia (20). Moreover, sodium-glucose cotransporter
2 inhibitors could induce transcriptional reprogramming of
cardiomyocytes and activate the housekeeping pathway of
autophagy, thereby acting as neurohormonal antagonists in the
treatment of HFrEF (21).
Our function enrichment analyses showed that reactive
oxygen species metabolic process and hormone receptor
play a vital role in HFrEF. The derivative of reactive
oxygen metabolites (DROM) production in the coronary
circulation had an association with HFrEF development, and
the DROM measurements benefited for the risk stratification
of HFrEF patients (22). Emerging in vivo studies implicated
that continuous infusion of corticotropin releasing hormone
receptor 2 (Crhr2) agonist could reduce LVEF in mice,
suggesting that Crhr2 blockade is a potential therapeutic
strategy for patients with chronic HF (23). Additionally,
blockade of mineralocorticoid receptor (hormone receptor) was
able to suppress elevated uric acid and glycogen synthase
kinase-3 (24).
In the human body, UA is the end production of metabolic
break up of purine nucleotides. Xanthine oxidase (XO)
and xanthine dehydrogenase are two enzymes responsible
for the UA metabolism and production. In chronic HF
patients, UA metabolism is upregulated due to higher activity
of XO and growing substrates of XO (25). Meanwhile,
reactive oxygen species (ROS, one item of BPs) and the
hydroxyl radical are produced. These free radicals further
lead to decreased nitric oxide release and increase oxidative
stress synthesis (26, 27). Consequently, inflammatory pathways
(e.g., TNF signaling pathway) and production of cytokines
are enhanced by the imbalance of oxidative stress and
decreased nitric oxide (28). Reactive oxygen and cytokines
could affect clinical characters by damaging the systolic
and diastolic energetics, depleting adenosine triphosphate of
the sarcoplasmic reticulum, and decreasing the anaerobic
threshold (29).
However, our work still has several limitations. Firstly,
the sample size of Xianyang Chronic Heart Failure
Prospective Cohort was small and the conclusion should
be interpretated in caution in the clinical practice. Secondly, this
is a prospective cohort study, some unmeasured factors
such as UA-lowering agents usage, insulin resistance,
peripheral vascular disease, postmenopausal state, peripheral
vascular disease might influence adverse outcomes.
Thirdly, the predicted mechanistic associations between
hyperuricemia and HFrEF need to be validated in appropriate
model systems.

In HFrEF patients, a lower UA predicts the recovery of LVEF
during follow-up, whereas a higher UA can be used as a predictor
of long-term adverse outcome events. Gene overlap and proteinprotein interaction network analyses provided a potential
mechanistic relationship between hyperuricemia and HFrEF.
In summary, this study offers a comprehensive framework
to explore disease relationship from population and networkbased perspectives.
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